

Novacyt S.A.
("Novacyt", the "Company" or the "Group")

Notice of Full Year 2022 Results and Investor Presentation

Paris, France and Eastleigh, UK – 17 April 2023 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will report its audited financial results for the year ended 31 December 2022 on Thursday, 27 April 2023.

Investor webinar

An investor webinar presentation by James McCarthy, Acting Chief Executive Officer, and Steve Gibson, Group Finance Director, will take place at 12.00pm BST on Thursday, 27 April 2023.

The webinar is open to all existing and potential investors and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation. Automated French subtitling will be available throughout the presentation.

Investors can sign up to Investor Meet Company for free and add to meet NOVACYT S.A. via:

<https://www.investormeetcompany.com/novacyt-sa/register-investor>

Investors who already follow NOVACYT S.A. on the Investor Meet Company platform will automatically be invited.

- End -

Contacts

Novacyt SA

James Wakefield, Non-Executive Chairman
James McCarthy, Acting Chief Executive Officer
+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470

Numis (Joint Broker)

James Black / Freddie Barnfield / Duncan Monteith
+44 (0)20 7260 1000

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com; y.petit@allegrafinance.com

Walbrook PR

Paul McManus/ Stephanie Cuthbert/ Anna Dunphy

+44 (0)20 7933 8780

novacyt@walbrookpr.com

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world's most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.

Novacyt is headquartered in Vélizy in France with offices in Stokesley and Eastleigh, UK, and is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com